Candidiasis
Candidiasis is a fungal infection caused by any species of the Candida genus, affecting various parts of the body including the mouth (thrush), vagina (yeast infection), and intestines (Intestinal Candidiasis). Common symptoms range from white patches and soreness in the mouth, genital itching and discharge, to more severe symptoms like fevers if the infection becomes systemic; treatment typically involves antifungal medications and probiotics.
Health Outcomes
- Adherence to Vaginal Mucosa
- Adhesion to Cervicovaginal Epithelial Cells
- Adverse Events from Probiotics
- Altered Lactobacilli Composition
- Altered Neutrophil Fungicidal Function
- Antifungal Activity Against Saccharomyces cerevisiae
- Antimicrobial Food Preservation
- Bacterial Vaginosis Colonization
- Changed Vaginal Microbiota Composition
- Colonization of Lactobacillus rhamnosus SD11 in Oral Cavity
- Colonization of Oral Cavity
- Confirmed Safety of Oral Probiotic Administration
- Decreased Abundance of Lactobacillaceae
- Disrupted Gut Microbiota Distribution
- Disrupted Microbial Cell Membrane Integrity
- Disrupted Mucosal Barrier
- Elevated Gut Yeast Levels
- Elimination of Candida glabrata
- Emergence of Fungal Infections
- Enhanced Adhesion Capacity to Oral Cells
- Enhanced Adhesion of Beneficial Bacteria
- Enhanced Anti-Infective Properties
- Enhanced Antimicrobial Capacity
- Enhanced Antimicrobial Peptide Levels
- Enhanced Antimicrobial Peptide Production
- Enhanced Antipathogenic Activity
- Enhanced Epithelial Cell Defense Against Candida Albicans
- Enhanced Epithelial Cell Defense Functions
- Enhanced Gut Probiotic Bacteria Propagation
- Enhanced Innate Immune Function
- Enhanced Pathogen Protection
- Enhanced Probiotic Activity
- Enhanced Probiotic Presence
- Enhanced Vaginal Health
- Enhanced Vaginal Immune Defense
- Enhanced β-Defensin 3 Activity
- Gut Colonization by Saccharomyces boulardii
- High Viability of Probiotic Lactobacillus crispatus BC4 in Cheese
- Improved Antagonistic Activity Against Undesirable Microorganisms
- Improved Antimicrobial Production
- Improved Clinical Outcomes in Candidiasis
- Improved Colonization Efficiency
- Improved Colonization Resistance to Pathogens
- Improved Cure Rate
- Improved Gut Dysbiosis
- Improved Health in HIV-Positive Subjects
- Improved Intestinal Flora
- Improved Lactobacillus Counts
- Improved Microbial Community Composition
- Improved Microbial Safety
- Improved Microbial Structures
- Improved Mucoadhesion
- Improved Mycological Cure Rate
- Improved Mycological Cure Rate of Oral Candidiasis
- Improved Niche Colonization
- Improved Oral Health (Reduced Tongue Coating)
- Improved Oral Microbial Balance
- Improved Oral Microbial Homeostasis
- Improved Oral pH
- Improved Phagocytic Activity
- Improved Probiotic Functionality
- Improved Probiotic Functionality for Functional Foods Development
- Improved Recovery from Antibiotic-Associated Diarrhea
- Improved Resistance to Infections
- Improved Resistance to Respiratory Candida Albicans Infection
- Improved Surface Properties for Reduced Microbial Colonization
- Improved Survival Rate Against Infection
- Improved Tolerance to Vaginal Suppository
- Improved Vaginal Barrier Integrity
- Improved Vaginal Colonization with Probiotics
- Improved Vaginal Flora
- Improved Vaginal Health Assessment Score
- Improved Vaginal Microbiota Balance
- Increased Antifungal Activity
- Increased Antifungal Peptide Production
- Increased Antifungal Peptides
- Increased Autochthonous Lactic Acid Bacteria Levels
- Increased Candida albicans Eradication
- Increased Exopolysaccharide Production
- Increased Expression of Antimicrobial Peptide Genes
- Increased Expressions of β-Defensins
- Increased Fecal Lactobacilli Content
- Increased Gastrointestinal Tract Colonization
- Increased Intestinal Epithelial Cell Adhesion
- Increased Lactic Acid Bacteria Levels
- Increased Lactobacilli Abundance
- Increased Lactobacilli Colonization
- Increased Lactobacilli Populations
- Increased Lactobacillus Count
- Increased Lactobacillus Population
- Increased Lactobacillus Species Count
- Increased Lactobacillus acidophilus in Crop at 14 Days
- Increased Levels of Lactobacillus Paracasei/Casei
- Increased Mucosal Adhesion
- Increased Oral Colonization of Lactiplantibacillus plantarum
- Increased Pathogen Resistance
- Increased Persistence of Probiotic Strains in Vaginal Tract
- Increased Probiotic Bacterial Count
- Increased Probiotic Consumption
- Increased Probiotic Levels
- Increased Probiotic Potential
- Increased Production of Antifungal Compounds
- Increased Salivary Antimicrobial Proteins
- Increased Salivary Lactobacilli Levels
- Increased Salivary pH
- Increased Vaginal Lactobacilli Presence
- Induction of Antimicrobial Chemokines
- Inhibited Fungal Hyphal Formation
- Inhibited Fungal Morphological Transformation
- Inhibited Growth of Candida Species
- Inhibited Pathogenic Microbes
- Inhibition of Yeast-to-Hyphae Transition in Candida Albicans
- Invasive Saccharomyces Infection
- Maintained Normal Vaginal Microbiota
- Maintained Vaginal Eubiosis
- Maintained Vaginal Homeostasis
- Maintained Vaginal Microbiota
- Modulated Vaginal Microbiota Diversity
- No Adverse Effects
- No Detected Virulence or Plasmid-Associated Safety Concerns
- No Significant Change in Streptococcus Mutans Quantification
- No Significant Impact on Vaginal Microbiota
- Non-Toxic Colonization
- Non-toxicity to Cervicovaginal Epithelial Cells
- Nonpathogenic for Mice
- Normalized Vaginal Microbiota
- Occurrence of Fungemia
- Plasmid-Mediated Niche Adaptation in Lactobacillaceae
- Potential Probiotic Health Effects
- Potentially Effective Antibacterial Proteins
- Presence of Lactobacillus gasseri BNR17 in Feces
- Presence of Lactobacillus salivarius CECT5713 in Feces
- Preventative Gut Colonisation
- Prevented Bloodstream Infection
- Prevention of Candida albicans Gastrointestinal Colonization
- Protection Against Bacterial Vaginosis
- Reduced Activated Effector CD4+ T Cells Percentage
- Reduced Antibiotic Damage to Microbiota
- Reduced Breastfeeding Cessation
- Reduced Candida Albicans Hyphal Formation
- Reduced Candida Albicans Propagation In Vivo
- Reduced Candida Albicans Survival
- Reduced Candida Counts
- Reduced Candida Morphogenesis
- Reduced Candida albicans Abundance in Cervicovaginal Region
- Reduced Candida albicans Aggregation
- Reduced Candida albicans Binding to Mucin
- Reduced Candida albicans Colonization
- Reduced Candida albicans Colony-Forming Units
- Reduced Candida albicans Filamentation
- Reduced Candida albicans Growth
- Reduced Candida spp. Activity
- Reduced Colonization of C. albicans in Intestines Post-Infection
- Reduced Colonization with Probiotic Lactobacilli
- Reduced Diarrhea in HIV-Positive Subjects
- Reduced Dysbiosis-Associated Bacteria Growth
- Reduced Escherichia coli Counts
- Reduced Expression of Hyphae-specific Genes
- Reduced Fluconazole Resistance
- Reduced Fungal Cell Count
- Reduced Fungal Growth
- Reduced Fungal Infection
- Reduced Fungal Load
- Reduced Fungal Load in Tissues
- Reduced Fungal Tissue Counts
- Reduced Harmful Intestinal Bacteria
- Reduced Harmful Microorganisms
- Reduced Incidence of Gynaecological Infections
- Reduced Intestinal Colonization of Candida albicans
- Reduced Lactobacillus Counts
- Reduced Leukocyte Influx During C. Albicans Challenge
- Reduced Localized Infection
- Reduced Microbial Growth
- Reduced Oral Candida Colonization
- Reduced Oral Candidiasis Risk
- Reduced Oral Lesion Size
- Reduced Oral Pathogen Growth
- Reduced Pathogen Activity
- Reduced Pathogen Adhesion
- Reduced Pathogen Adhesion to Buccal Epithelial Cells
- Reduced Pathogen Adhesion to Vaginal Epithelial Cells
- Reduced Pathogen Colonization
- Reduced Pathogen Incidence
- Reduced Pathogen Infection
- Reduced Pathogen Viability
- Reduced Pathogenic Fungal Activity
- Reduced Pathogenic Load
- Reduced Pathogenic Microorganisms in the Intestine
- Reduced Prevalence of Bacterial Vaginosis
- Reduced Risk of Gynaecological Infections
- Reduced Salivary Lactoferrin Levels
- Reduced Severity of Denture Stomatitis
- Reduced Severity of Oral Candidiasis
- Reduced Symptoms in VVC Patients
- Reduced Treatment Duration
- Reduced Urogenital Infections
- Reduced Urogenital Pathogen Activity
- Reduced Urogenital Pathogen Growth
- Reduced VVC Recurrence
- Reduced VVC Symptoms
- Reduced Vaginal Candidiasis Symptoms
- Reduced Vaginal Colonization
- Reduced Vaginal Dysbiosis-Associated Infection Risk
- Reduced Vaginal Inflammation
- Reduced Vaginal Pathogens
- Reduced Vaginal Symptom Score
- Reduced Vaginal Yeast Colonization
- Reduced Vaginal Yeast Infections
- Reduced Vaginal Yeast Levels
- Reduced Vaginitis Recurrence
- Reduced Virulence / Lower Risk of Fungemia
- Reduced Yeast-to-Hyphae Transition
- Reestablished Intestinal Microecology
- Regressed Esophagitis
- Regulated Microbial Metabolism
- Restored Endogenous Microbiota Equilibrium
- Restored Normal Microbiota
- Restored Urogenital Tract Microbiome
- Safe Use of Lactobacillus reuteri NCIMB 30242
- Safety in Treatment for Bacterial Vaginosis
- Safety of Lactobacillus crispatus Consumption
- Safety of Probiotic Supplementation
- Suppressed Pathogenic Growth
- Sustained Relief from Recurrent Vulvovaginal Candidiasis
- Treated Oral Candidosis
- Vaginal Colonization by Lactobacillus Strains
- Vaginitis Cure or Remission Rate
- Viability of Probiotic Bacteria in Cheese
- Viable Probiotic Strain Recovery
- Yeast Migration from Intestine to Vagina